GC Pharma has been strengthening partnerships with pharmaceutical and biohealth companies in Korea and abroad by signing a series of copromotion agreements.

After the company signed a copromotion agreement for GSK’s shingles vaccine ‘Shingrix’ at the end of last year, the company recently also signed an agreement to copromote Sanofi's anti-platelet agent ‘Plavix.' Also, earlier this year, the company expanded its sales agreement with BMS on selling the company’s hepatitis B treatment, ‘Baraclude.’

The industry interpreted this as the company’s move to diversify its business structure, focusing on blood derivative products and vaccines and securing a cash cow through exte